During the past decade, Shaohong Yin conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Shaohong Yin" are "Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma" (1 trials), "Bioequivalence" (1 trials) and "Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma" (1 trials). Many other conditions were trialed in "Shaohong Yin" in a lesser frequency.

Most popular intervention types in "Shaohong Yin" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "F182112" (1 trials), "Orlistat 60mg Cap" (1 trials) and "Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "Shaohong Yin" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Shaohong Yin". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Shaohong Yin, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Shaohong Yin, 2 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".